Literature DB >> 10479128

Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons.

D L Ellenberger1, P S Sullivan, J Dorn, C Schable, T J Spira, T M Folks, R B Lal.   

Abstract

Persons who were human immunodeficiency virus type 1 (HIV-1)-infected but who remained persistently seronegative (HIPS) on HIV-1 antibody tests were examined through AIDS case surveillance. Six such individuals (HIPS-1 to -4, -7, and -9) were examined to determine whether their persistent seronegativity was attributable to immune dysfunction or infection with atypical HIV. Of the 6, 4 had antibody titers to at least 1 other common pathogen. In vitro stimulation of peripheral blood mononuclear cells from HIPS-4 and HIPS-7 with pokeweed mitogen or phosphorothioate oligodeoxynucleotide (direct B cell mitogen) did not produce HIV-1-specific antibody. Reconstitution experiments with recombinant interleukin (rIL)-4 and rIL-12 also had no impact on antibody production. Virus isolates from HIPS-4 and -9 were R5X4-tropic, whereas HIPS-7 was CCR5-tropic only. Sequence analysis of long terminal repeat, p24, and env gp41 did not reveal any specific mutation, and phylogenetic analysis confirmed that all 6 virus specimens were HIV-1 subtype B. These data suggest that the lack of a detectable antibody response in these patients may be the result of immune dysfunction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479128     DOI: 10.1086/315024

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants.

Authors:  W H Koch; P S Sullivan; C Roberts; K Francis; R Downing; T D Mastro; J Nkengasong; D Hu; S Masciotra; C Schable; R B Lal
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.

Authors:  J Dorn; S Masciotra; C Yang; R Downing; B Biryahwaho; T D Mastro; J Nkengasong; D Pieniazek; M A Rayfield; D J Hu; R B Lal
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

Authors:  E Randall Lanier; Roger G Ptak; Bernhard M Lampert; Laurie Keilholz; Tracy Hartman; Robert W Buckheit; Marie K Mankowski; Mark C Osterling; Merrick R Almond; George R Painter
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

4.  Rapid HIV progression during acute HIV-1 subtype C infection in a Mozambican patient with atypical seroconversion.

Authors:  Cesar Velasco; Erica Parker; Lucia Pastor; Abel Nhama; Salesio Macuacua; Inácio Mandomando; Julià Blanco; Denise Naniche
Journal:  Am J Trop Med Hyg       Date:  2015-01-26       Impact factor: 2.345

5.  Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes.

Authors:  Bouchra Zerhouni; Julie A E Nelson; Kunal Saha
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function.

Authors:  Helene B Bernstein; Guangwu Wang; Mary C Plasterer; Jerome A Zack; Parthasarathy Ramasastry; Shannon M Mumenthaler; Christina M R Kitchen
Journal:  Virology       Date:  2009-02-28       Impact factor: 3.616

7.  A case of seronegative HIV-1 infection.

Authors:  Adam M Spivak; Tim P Brennan; Karen A O'Connell; Emily Sydnor; Thomas M Williams; Robert F Siliciano; Joel E Gallant; Joel N Blankson
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

8.  Fatal HIV encephalitis in HIV-seronegative patients.

Authors:  Troy M Martin; Josiah D Rich
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

9.  Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor.

Authors:  Orapun Metadilogkul; Vichai Jirathitikal; Aldar S Bourinbaiar
Journal:  J Biomed Biotechnol       Date:  2008-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.